The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer.


Journal

Mucosal immunology
ISSN: 1935-3456
Titre abrégé: Mucosal Immunol
Pays: United States
ID NLM: 101299742

Informations de publication

Date de publication:
07 2019
Historique:
received: 25 01 2019
accepted: 13 05 2019
revised: 09 05 2019
pubmed: 6 6 2019
medline: 11 4 2020
entrez: 6 6 2019
Statut: ppublish

Résumé

The composition of immune infiltrates strongly affects the prognosis of patients with colorectal cancer (CRC). Interleukin (IL)-33 and regulatory T cells (Tregs) in the tumor microenvironment have been separately implicated in CRC; however their contribution to intestinal carcinogenesis is still controversial. Here, we reveal that IL-33 signaling promotes CRC by changing the phenotype of Tregs. In mice with CRC, tumor-infiltrating Tregs preferentially upregulate IL-33 receptor (ST2), and IL-33/ST2 signaling positively correlates with tumor number and size. Transcriptomic and flow cytometry analyses demonstrate that ST2 expression induces a more activated and migratory phenotype in FOXP3

Identifiants

pubmed: 31165767
doi: 10.1038/s41385-019-0176-y
pii: S1933-0219(22)00277-X
pmc: PMC7746527
doi:

Substances chimiques

Il1rl1 protein, mouse 0
Interleukin-1 Receptor-Like 1 Protein 0
Interleukin-33 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

990-1003

Références

Liu, X. et al. Structural insights into the interaction of IL-33 with its receptors. Proc. Natl Acad. Sci. USA 110, 14918–14923 (2013).
pubmed: 23980170
Moussion, C., Ortega, N. & Girard, J. P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin'? PLoS ONE 3, e3331 (2008).
pubmed: 18836528 pmcid: 2556082
Liew, F. Y., Girard, J. P. & Turnquist, H. R. Interleukin-33 in health and disease. Nat. Rev. Immunol. 16, 676–689 (2016).
pubmed: 27640624
Coyle, A. J. et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J. Exp. Med. 190, 895–902 (1999).
pubmed: 10510079 pmcid: 2195643
Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564–568 (2014).
pubmed: 25043027 pmcid: 4339042
Matta, B. M. et al. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J. Immunol. 193, 4010–4020 (2014).
pubmed: 25217167 pmcid: 4185240
Spence, A., Klementowicz, J. E., Bluestone, J. A. & Tang, Q. Targeting Treg signaling for the treatment of autoimmune diseases. Curr. Opin. Immunol. 37, 11–20 (2015).
pubmed: 26432763 pmcid: 4679451
Chaudhary, B. & Elkord, E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines 4, 1–25 (2016).
Erdman, S. E. & Poutahidis, T. Roles for inflammation and regulatory T cells in colon cancer. Toxicol. Pathol. 38, 76–87 (2010).
pubmed: 20019355
Frey, D. M. et al. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int. J. Cancer 126, 2635–2643 (2010).
pubmed: 19856313
Clarke, S. L. et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 1, e129 (2006).
pubmed: 17205133 pmcid: 1762416
Sakaguchi, S., Vignali, D. A., Rudensky, A. Y., Niec, R. E. & Waldmann, H. The plasticity and stability of regulatory T cells. Nat. Rev. Immunol. 13, 461–467 (2013).
pubmed: 23681097
Hori, S. Lineage stability and phenotypic plasticity of Foxp3(+) regulatory T cells. Immunol. Rev. 259, 159–172 (2014).
pubmed: 24712465
DuPage, M. & Bluestone, J. A. Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat. Rev. Immunol. 16, 149–163 (2016).
pubmed: 26875830
Maywald, R. L. et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc. Natl Acad. Sci. USA 112, E2487–E2496 (2015).
pubmed: 25918379
Mertz, K. D. et al. The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. Oncoimmunology 5, e1062966 (2016).
pubmed: 26942077
Zhang, Y. et al. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis. Mol. Carcinog. 56, 272–287 (2017).
pubmed: 27120577
Neufert, C., Becker, C. & Neurath, M. F. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat. Protoc. 2, 1998–2004 (2007).
pubmed: 17703211
Pastille, E. et al. Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer. Cancer Res. 74, 4258–4269 (2014).
pubmed: 24906621
Kim, H. J. et al. Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. Science 350, 334–339 (2015).
pubmed: 26472910 pmcid: 4627635
Sugimoto, N. et al. Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int. Immunol. 18, 1197–1209 (2006).
pubmed: 16772372
Agrawal, D. et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl Cancer Inst. 94, 513–521 (2002).
pubmed: 11929952
Nguyen, L. P. et al. Role and species-specific expression of colon T cell homing receptor GPR15 in colitis. Nat. Immunol. 16, 207–213 (2015).
pubmed: 25531831
Akram, I. G., Georges, R., Hielscher, T., Adwan, H. & Berger, M. R. The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis. Tumour Biol. 37, 2461–2471 (2016).
pubmed: 26383527
Li, Y. R. & Yang, W. X. Myosins as fundamental components during tumorigenesis: diverse and indispensable. Oncotarget 7, 46785–46812 (2016).
pubmed: 27121062 pmcid: 5216836
Wang, Z. et al. Endothelin promotes colorectal tumorigenesis by activating YAP/TAZ. Cancer Res. 77, 2413–2423 (2017).
pubmed: 28249901 pmcid: 6724531
Blatner, N. R. et al. Expression of RORgammat marks a pathogenic regulatory T cell subset in human colon cancer. Sci. Transl. Med. 4, 164ra159 (2012).
pubmed: 23241743 pmcid: 3762575
Hyun, Y. S. et al. Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis 33, 931–936 (2012).
pubmed: 22354874
Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).
pubmed: 24202395 pmcid: 3954707
Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436–444 (2008).
Mager, L. F., Wasmer, M. H., Rau, T. T. & Krebs, P. Cytokine-induced modulation of colorectal cancer. Front. Oncol. 6, 96 (2016).
pubmed: 27148488 pmcid: 4835502
Wasmer, M. H. & Krebs, P. The role of IL-33-dependent inflammation in the tumor microenvironment. Front. Immunol. 7, 682 (2016).
pubmed: 28119694
Zhuo, C. et al. FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer. Immunol. Res. 61, 338–347 (2015).
pubmed: 25608795
Eissmann, M. F. et al. Interleukin 33 signaling restrains sporadic colon cancer in an interferon-gamma-dependent manner. Cancer Immunol. Res. 6, 409–421 (2018).
pubmed: 29463593
Stenstad, H. et al. Gut-associated lymphoid tissue-primed CD4+ T cells display CCR9-dependent and -independent homing to the small intestine. Blood 107, 3447–3454 (2006).
pubmed: 16391017
Bondar, C. et al. Role of CXCR3/CXCL10 axis in immune cell recruitment into the small intestine in celiac disease. PLoS ONE 9, e89068 (2014).
pubmed: 24586509 pmcid: 3930692
Mencarelli, A. et al. Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis. Sci. Rep. 6, 30802 (2016).
pubmed: 27492684 pmcid: 4974621
Adamczyk, A. et al. Differential expression of GPR15 on T cells during ulcerative colitis. JCI Insight 2, https://doi.org/10.1172/jci.insight.90585 (2017).
Chang, L. Y. et al. Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res. 72, 1092–1102 (2012).
pubmed: 22282655
Komai-Koma, M. et al. IL-33 is a chemoattractant for human Th2 cells. Eur. J. Immunol. 37, 2779–2786 (2007).
pubmed: 17853410
Siede, J. et al. IL-33 receptor-expressing regulatory T cells are highly activated, Th2 biased and suppress CD4 T cell proliferation through IL-10 and TGFbeta release. PLoS One 11, e0161507 (2016).
pubmed: 27548066 pmcid: 4993514
Komatsu, N. et al. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc. Natl Acad. Sci. USA 106, 1903–1908 (2009).
pubmed: 19174509
Downs-Canner, S. et al. Suppressive IL-17A(+)Foxp3(+) and ex-Th17 IL-17A(neg)Foxp3(+) Treg cells are a source of tumour-associated Treg cells. Nat. Commun. 8, 14649 (2017).
pubmed: 28290453 pmcid: 5355894
Pascual-Reguant, A. et al. TH17 cells express ST2 and are controlled by the alarmin IL-33 in the small intestine. Mucosal Immunol. 10, 1431–1442 (2017).
pubmed: 28198366
Amicarella, F. et al. Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut 66, 692–704 (2017).
pubmed: 26719303
Chen, M. L. et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl Acad. Sci. USA 102, 419–424 (2005).
pubmed: 15623559
Francisco, L. M. et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206, 3015–3029 (2009).
pubmed: 20008522 pmcid: 2806460
Townsend, M. J., Fallon, P. G., Matthews, D. J., Jolin, H. E. & McKenzie, A. N. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 191, 1069–1076 (2000).
pubmed: 10727469 pmcid: 2193113
Chen, W. Y., Hong, J., Gannon, J., Kakkar, R. & Lee, R. T. Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. Proc. Natl Acad. Sci. USA 112, 7249–7254 (2015).
pubmed: 25941360
Wing, K. et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271–275 (2008).
pubmed: 18845758
Kim, J. M., Rasmussen, J. P. & Rudensky, A. Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8, 191–197 (2007).
pubmed: 17136045
Lin, W. et al. Regulatory T cell development in the absence of functional Foxp3. Nat. Immunol. 8, 359–368 (2007).
pubmed: 17273171
Fodde, R. et al. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc. Natl Acad. Sci. USA 91, 8969–8973 (1994).
pubmed: 8090754
Kucherlapati, M. H. et al. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology 138, 993–1002 e1001 (2010).
pubmed: 19931261
Simillion, C., Liechti, R., Lischer, H. E., Ioannidis, V. & Bruggmann, R. Avoiding the pitfalls of gene set enrichment analysis with SetRank. BMC Bioinforma. 18, 151 (2017).

Auteurs

Eva Pastille (E)

Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Marie-Hélène Wasmer (MH)

Institute of Pathology, University of Bern, Bern, Switzerland.
Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.

Alexandra Adamczyk (A)

Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Vivian P Vu (VP)

Institute of Pathology, University of Bern, Bern, Switzerland.
Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.

Lukas F Mager (LF)

Department of Physiology and Pharmacology, Snyder Institute of Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Canada.

Nhi Ngo Thi Phuong (NNT)

Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Vittoria Palmieri (V)

Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Cedric Simillion (C)

Department of Clinical Research, University of Bern, Bern, Switzerland.
Interfaculty Bioinformatics Unit and Swiss Institute of Bioinformatics, University of Bern, Bern, Switzerland.

Wiebke Hansen (W)

Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Stefan Kasper (S)

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany.

Martin Schuler (M)

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany.

Beat Muggli (B)

Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Kathy D McCoy (KD)

Department of Physiology and Pharmacology, Snyder Institute of Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Canada.

Jan Buer (J)

Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Inti Zlobec (I)

Institute of Pathology, University of Bern, Bern, Switzerland.

Astrid M Westendorf (AM)

Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. astrid.westendorf@uk-essen.de.

Philippe Krebs (P)

Institute of Pathology, University of Bern, Bern, Switzerland. philippe.krebs@pathology.unibe.ch.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH